Sub Banner Image

Goldman Sachs Just Upgraded This Blue-Chip Stock. Should You Buy It Now?

Equities

Sushree Mohanty

·

April 18, 2025

·

Barchart

With a strong pipeline, this pharmaceutical powerhouse is positioning itself as a dominant force in the future of medicine.

More from

Barchart

More

Equities

Articles

Trending News

Enjoy premium content in your inbox.

You're in! Check your email to learn more.
Oops! Something went wrong while submitting the form.